[ad_1]
The British government has unveiled its new action plan to control antimicrobial resistance.
NHS England and the National Institute for Health & Care Excellence (NICE) will explore a new payment model that remunerates pharmaceutical companies based on the value of their medicines for the NHS, by encouraging the development of innovative new antimicrobial drugs.
In announcing the new plan, Health and Social Affairs Secretary Matt Hanbad said that antimicrobial resistance was a great danger to humanity, just like climate change or war, and called for an urgent global response.
"Everyone of us benefits from antibiotics, but we take them too easily for granted, and I shudder at the thought of a world in which their power is diminished," he said. .
At present, pharmaceutical companies are faced with the dilemma that their new, high-investment super-drugs will be sold directly to the NHS and used as economically as possible, meaning that sales volumes will be reduced.
Efforts are underway to dissociate the correlation between the revenues of the phrama and the volume of drugs sold, through new incentives rewarding pharmaceutical innovation.
Dr. Peter Jackson, Executive Director of the AMR Center, which coordinates research on new antibiotics in the UK, called the new plan a crucial step in the fight against AMR.
"This new approach will provide a real boost for pharmaceutical companies developing new AMR medicines, especially for SMEs that do most of the research in the UK. It is also an important signal to the private investor community to return to the brand and support businesses engaged in R & D on AMR. "
700,000 deaths a year worldwide due to a drug-resistant infection: Dr. Peter Jackson talks about antimicrobial resistance at Innovations 2018
Without proper action, antibiotic resistance is expected to kill 10 million people annually by 2050. The number of drug-resistant blood flow infections, for example, has increased by 35% between 2013 and 2017.
"At the moment, the oldest antibiotics are mostly generic drugs, sold at low prices and with wide availability, uncontrolled in some parts of the world," said Dr. Jackson. "This is one of the reasons why microbes have evolved quickly to resist the most common clbades of antibiotics in the medicine cabinet. And with international mobility, these resistant microbes can spread quickly around the world.
Without effective antibiotics, daily medical procedures such as caesareans or hip replacements could become too dangerous.
Clinicians now see superbugs that resist more than one type of antibiotic or even all. This has led to cases such as the recent super-gonorrhea infection in two British women.
The announcement of the NHS should give other countries in the world the way to go quickly and introduce their own incentives for R & D on antibiotics.
Dr. Chris Doherty, general manager of Alderley Park in Cheshire, whose companies are working on new antibiotics, said; "The government's new strategy is attacking market failures in the development of antibiotic drugs.
"RMA is a complex challenge, but science can only solve it if the funding mechanism for this unique problem is reworked. The consequences of such a failure would affect us all. "
The new plan – which also covers animals and the environment – also aims to reduce the number of resistant infections and help clinicians prescribe appropriately. As part of the strategy, the use of antibiotics in humans will be reduced by 15%.
The government will use new technologies to collect patient data to help clinicians know when to use and store antibiotics in treatment.
Other goals include reducing the number of drug-resistant infections by 10% by 2020 and preventing at least 15,000 patients a year from contracting infections resulting from their health care. Here 2024.
[ad_2]
Source link
